Iceland's Actavis has upped its bid to acquire Croatia's Pliva to $139 a share, surpassing the latest offer from Barr. But analysts say the bidding war isn't over yet.

Iceland’s Actavis yesterday upped the ante in its battle with US firm Barr Laboratories to walk down the aisle with Croatian firm Pliva, raising its bid to 795 kuna ($139) per share and knocking ...

An explosion and fire at the Pliva plant in Croatia has turned fatal. One of the 9 workers injured in the fire March 16 has died and another remains hospitalized, the company said in a statement ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Actavis on Monday appeared to concede defeat in the takeover battle for Pliva, the Croatian drugs manufacturer.

On March 30, in PLIVA, Inc. v. Mensing (consolidated with Actavis Elizabeth, L.L.C. v. Mensing), the Court will hear oral argument regarding whether a state can hold manufacturers liable for failing ...

Competition for Croatia’s largest company, Pliva, which put itself up for sale after an unsolicited approach from Iceland’s Actavis, has been particularly fierce. Barr Pharmaceuticals ...

The US Federal Trade Commission has voted unanimously to approve Barr Pharmaceuticals’ acquisition of Croatian group Pliva for around $2.5 billion, but Barr will have to sell off some product lines to ...